Anti-Human CD20 (Rituximab) - PE Biosimilar (IVMB0525)

Product Name:	Anti-Human CD20 (Rituximab) - PE
SKU:	IVMB0525
Size:	50 µg
Antibody Type:	Biosimilar Recombinant Human Monoclonal Antibody
Clone:	10F381
Target:	CD20
Isotype:	Human IgG1κ
Host Species:	Human
Reactivity:	Human/Rhesus Monkey/Cynomolgus Monkey

Applications:	FC
Expression Host:	HEK-293 Cells
FC Effector Activity:	Active
Synonyms:	B1; S7; Bp35; CVID5; MS4A2; LEU-16; MS4A1; membrane spanning 4-domains A1
Product Concentration:	0.2 mg/ml
Excitation Laser:	Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Immunogen:	Human lymphoblastoid cell line SB.
Applications and Recommended Usage:	FC The suggested concentration for Rituximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Antigen Distribution:	CD20 is primarily found on the surface of immune system B cells. CD20 is highly expressed in the lymph node, and to a lesser extent, the spleen and appendix.
Formulation:	This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Specificity:	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Rituximab. Clone 10F381 recognizes human CD20. This product is for research use only.

CD20 is a 33-37 kD transmembrane-spanning phosphoprotein found on the surface of developing B-cells and various B-cell malignancies. CD20 is a popular target for mAb therapy because depleting developing B-cells generally does not cause permanent side effects (due to the fact that mature plasma cells and B-cell progenitors do not express CD20 and that there is limited expression of CD20 among other cell lineages). Rituximab is a chimeric monoclonal antibody that binds to CD20. The precise function of CD20 is still unknown. However, it is suspected to play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration, and allowing the activation of B cells. Rituximab is used to treat some autoimmune diseases and types of cancer such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis among others. The Fc portion of Rituximab mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen) and also induces apoptosis of CD20+ cells. This ultimately results in the elimination of B cells (including the cancerous ones) from the body, and thus allows a new population of healthy B cells to develop from lymphoid stem cells. Anti-Human CD20 (Rituximab) utilizes the same variable regions from the therapeutic antibody Rituximab making it ideal for research projects.

Regulatory Status:	Research Use Only (RUO). Non-Therapeutic.
Storage and Handling:	This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C.Do not freeze.
Research Area:	Biosimilars